Scarica l'app Stockscreener
122.87
0.71%
0.87
Dopo l'orario di chiusura:
127.49
4.62
+3.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Insmed and VytlOne: A Groundbreaking Partnership in Rare Disease Innovation - AInvest
VytlOne Announces New Partnership with Insmed - Yahoo Finance
Insmed stock downgraded at Morgan Stanley (INSM:NASDAQ) - Seeking Alpha
Insmed stock price target raised to $154 from $135 at TD Cowen on Brinsupri approval - Investing.com Canada
Insmed stock price target raised to $138 from $120 at RBC Capital - Investing.com Canada
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week - Stocktwits
UBS Adjusts Insmed Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - Yahoo Finance
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
Insmed wins FDA approval for future blockbuster Brinsupri - Yahoo Finance
Mizuho raises Insmed stock price target to $165 following Brinsupri approval - Investing.com Canada
Morgan Stanley Downgrades Insmed to Equal Weight From Overweight, Adjusts Price Target to $126 From $112 - MarketScreener
Mizuho Adjusts Price Target on Insmed to $165 From $130, Maintains Outperform Rating - MarketScreener
Mizuho Raises Price Target for Insmed (INSM) to $165 | INSM Stoc - GuruFocus
Insmed secures FDA approval for Brinsupri to treat NCFB - World Pharmaceutical Frontiers
Insmed stock price target raised to $140 at UBS on Brinsupri approval - Investing.com Canada
Jefferies Raises Price Target on Insmed (INSM) to $148 | INSM St - GuruFocus
Insmed gets first FDA approval for bronchiectasis - pharmaphorum
Insmed stock rating downgraded to Equalweight by Morgan Stanley - Investing.com Canada
Insmed (INSM) Receives Positive Analyst Ratings and Price Target Increases - AInvest
Insmed (INSM) Surges 8.07% as Bullish Candlesticks and MACD Golden Cross Signal 65% Outperformance Probability - AInvest
Insmed Surges 8.07% on FDA Approval as $870M Trading Volume Hits Top 500 Daily Rank - AInvest
US FDA approves Insmed's drug as first treatment for a chronic lung disease - Reuters
Wells Fargo Raises Price Target for INSM to $140, Maintains Over - GuruFocus
Insmed: Wells Fargo Reiterates Overweight, Raises PT to $140 from $130 - AInvest
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - AOL.com
FDA Approves Insmed’s Brensocatib as First Therapy for Non-Cystic Fibrosis Bronchiectasis - geneonline.com
Insmed gains US approval of lung disease drug forecast to be blockbuster - BioPharma Dive
Brinsupri dose choice means bronchiectasis upside, Insmed says - BioWorld MedTech
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - Investor's Business Daily
Jefferies raises Insmed stock price target to $148 on Brinsupri approval - Investing.com Canada
Insmed scores FDA clearance for Brinsupri in NCFB - BioWorld MedTech
FDA Approves Insmed's Brinsupri for Chronic Lung Disease Treatment - AInvest
Why Is Insmed Stock Trading Higher TodayInsmed (NASDAQ:INSM) - Benzinga
US FDA approves Insmed’s drug as first treatment for a chronic lung disease - The Mighty 790 KFGO
Insmed gets FDA approval for the first DPP1 inhibitor, in lung disease - Endpoints News
Insmed's Brinsupri: A Blockbuster Launch in a Neglected Market - AInvest
Insmed stock rises on FDA nod for lung disorder drug Brinsupri - Seeking Alpha
Insmed stock surges after FDA approves first NCFB treatment By Investing.com - Investing.com Canada
Insmed's FDA Approval of Brinsupri: A Strategic Win in the Orphan Drug Market and Its Implications for Shareholder Value - AInvest
US FDA approves Insmed's lung disease drug - Reuters
Insmed Drug Wins First US Approval for Debilitating Lung Disease - Bloomberg.com
FDA Makes History: First-Ever Treatment for 500,000 Non-Cystic Fibrosis Bronchiectasis Patients Gets Approval - Stock Titan
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Insmed's 3.28% Two-Day Rally Fueled by Strong Candlestick Momentum and Bullish Moving Averages - AInvest
Insmed Surges 3.05% on 28.6% Japan Revenue Spike as $370M Volume Ranks 271st in Market Activity - AInvest
Insmed Hovers Near 110 Resistance As Technicals Signal Consolidation Risk - AInvest
Insmed stock hits 52-week high at 113.17 USD By Investing.com - Investing.com Nigeria
Insmed stock hits 52-week high at 113.17 USD - Investing.com
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock - Yahoo Finance
Liquidia: Uncertainty Has Always Been A Buying Opportunity (LQDA) - Seeking Alpha
Strategic Implications of Insmed's Lock-Up Expiry and $650M Equity Raise on Shareholder Value and Market Position - AInvest
Insmed's Post-Lock-Up RSU Liquidity and Market Implications - AInvest
Will Insmed Incorporated bounce back from current support3-Year Equity Summary With Setup Insights - Newser
Insmed Incorporated (NASDAQ:INSM) Q2 2025 Earnings Call Transcript - Insider Monkey
Real time scanner hits for Insmed Incorporated explainedBollinger Band Squeeze and Expansion Analysis - Newser
H.C. Wainwright Maintains Buy Rating on Insmed with $120 Price Target - AInvest
Insmed's $350M Trade Ranks 273rd as High-Volume Strategy Generates 166% Alpha - AInvest
Insmed's Q2 net loss reaches $322M, but shares surge 68% amidst revenue guidance and Russell index inclusion. - AInvest
Insmed (INSM) Reports Increased Losses But Reiterates 2025 Revenue Guidance - Yahoo Finance
Insmed stock price target raised to $120 from $108 at RBC Capital - Investing.com Australia
UBS Adjusts Price Target on Insmed to $133 From $124, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $111.26 to $135 - 富途牛牛
RBC Raises Price Target on Insmed to $120 From $108, Keeps Outperform Rating - MarketScreener
Insmed price target raised to $133 from $124 at UBS - TipRanks
Insmed: Q2 Earnings Snapshot - Connecticut Post
Insmed Reports Q2 Earnings with 19% ARIKAYCE Revenue Growth and Positive TPIP Study Results - AInvest
Insmed Inc (INSM) Q2 2025 Earnings Call Highlights: Strong Finan - GuruFocus
1.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):